Oklahoma Proton Center Opens State of the Art Ocular Melanoma Program

OKLAHOMA CITY, OK / ACCESSWIRE / January 7, 2020 / Oklahoma Proton Center has opened an ocular melanoma treatment program that is one of just a handful of proton focused programs in the country.

Ocular Melanoma is a rare malignancy that develops in the pigmented part of the eye, affecting roughly 2,200 people per year in the U.S. Treatment options in Oklahoma have historically included local resection, radioactive plaque, enucleation, and Gamma Knife. Proton Therapy offers a non-invasive more precise approach to treating this cancer.

Dr. John Chang was part of the Ocular Melanoma program at the Northwestern Proton Center in Chicago, IL before joining Oklahoma Proton Center earlier this year. “Proton therapy is a proven method to treat Ocular Melanoma. We are excited to be the first to offer this treatment to patients in the region.”

Studies from Massachusetts General Hospital and the Paul Scherrer Institute have shown benefits for patients treated with proton therapy including high local control and survival rates of 95% or better along with preservation of the natural eye and sparing of healthy tissue.

A survey of available studies done by the Mayo Clinic assessing charged particle therapy, including proton therapy, for uveal melanoma found that the “rate of local recurrence was significantly less” with proton therapy than with brachytherapy and proton therapy was also associated with lower retinopathy and cataract formation rates.1 This was based on data from 27 studies and a total of 8,809 patients.

Most major insurance companies, including Blue Cross Blue Shield of Oklahoma, UnitedHealthcare, and Medicare provide coverage for proton therapy for the treatment of ocular melanoma.

Treatments take about 30 minutes each day and occur over a total of 5 days.

For more information about the program or to meet with a doctor, patients can contact Oklahoma Proton Center at (405) 773 – 6700 or visit the center’s website at www.okcproton.com

About Oklahoma Proton Center

The Oklahoma Proton Center opened in August of 2009 as the 6th proton center in the United States and remains one of just 32 active proton centers in the United States. The clinical team at the facility is one of the most experienced in the industry and the center has been a leader and pioneer in the field for the past 10 years. The center has four treatment rooms and treats as many as 70+ patients per day.

About Proton Therapy

Proton Therapy is the most precise form of radiation treatment for cancer available today. The physics of protons allow physicians to deliver them into cancer cells where they stop thus avoiding damage to surrounding healthy tissue and critical organs. Proton Therapy is routinely used at some of the nation’s leading cancer hospitals and more than 200,000 patients have been successfully treated worldwide. Proton therapy can be used to treat most solid tumors including diagnoses such as breast, lung, head and neck, gastrointestinal, prostate, brain, and other cancers.

  1. Wang, et al. Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):18-26.

CONTACT:

David Raubach
Chief Development Officer
(918) 798-9160
David.Raubach@okcproton.com

SOURCE: Oklahoma Proton Center

View source version on accesswire.com:
https://www.accesswire.com/572303/Oklahoma-Proton-Center-Opens-State-of-the-Art-Ocular-Melanoma-Program

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

17 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

17 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

2 days ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

2 days ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

2 days ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

2 days ago